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Case Report
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We report a case of posterior scleritis effectively managed with intravitreal bevacizumab. A 71-year-old woman was 
diagnosed with posterior scleritis. Although she was initially treated with systemic steroids, her clinical presentation 
deteriorated. She was then treated with a single intravitreal injection of bevacizumab and aqueous humor collection. 
The aqueous level of vascular endothelial growth factor prior to the intravitreal injection was 880.51 pg/mL, greater 
than that in the healthy control group (p < 0.001). One month later, the scleritis was completely resolved, and the pa-
tient remained stable during six months of follow-up. Intravitreal bevacizumab appears to be an effective adjuvant 
therapy for patients with posterior scleritis. 
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Posterior scleritis is an uncommon and under-recognized 
form of scleral inflammation [1]. The majority of patients 
with idiopathic posterior scleritis respond well to treatment 
with non-steroidal anti-inflammatory drugs. Here, we report 
a patient with posterior scleritis who had a favorable re-
sponse to intravitreal bevacizumab. This patient had elevated 
levels of vascular endothelial growth factor (VEGF) and in-
terlukin (IL)-8 in the aqueous humor; serum levels of these 
molecules were not increased.
Case Report
A 71-year-old woman presented to our clinic for evalua-
tion of right ocular pain and loss of visual acuity for the pre-
vious week. On ophthalmic examination, visual acuity was 
20 / 50 in the right eye (OD). There was an anterior chamber 
reaction (++) and a vitreous cell reaction (+) in the OD. 
Fundus examination revealed disc swelling, peripheral se-
rous retinal detachment, and edema at the site of a macular 
lesion (Fig. 1A). Fluorescein angiography revealed disc ede-
ma and vascular leakage (Fig. 1B). Posterior scleral thicken-
ing, choroidal effusion, and serous retinal detachment were 
demonstrated on ocular ultrasonography, suggesting posteri-
or scleritis (Fig. 1C). Other laboratory findings were normal 
and she had no systemic disease. The patient was treated with 
prednisolone (1 mg/kg orally) and topical prednisolone (1%). 
After three days of treatment, the serous and choroidal de-
tachment worsened, and her visual acuity decreased to hand 
movement. The patient agreed to proceed with intravitreal 
bevacizumab treatment (1.25 mg/0.1 mL) after informed 
consent for the off-label use of this drug was obtained. 
The patient was given a single intravitreal bevacizumab 
injection. Aqueous humor and blood samples were obtained 
prior to injection. One day later, the ocular pain and serous 
macular detachment were considerably reduced; after one 
month, the scleritis had completely remitted (Fig. 1D). The 
dose of oral prednisolone was gradually reduced over the 
course of one month. Further improvement was noted, and 
the patient remained stable during six months of follow-up 
with a visual acuity of 20 / 40 in the OD.
Concentrations of VEGF and IL-8 were measured using 
suspension bead array technology on a Luminex TM 100 IS 
system (Luminex Corp., Austin, TX, USA). Aqueous humor 
and blood samples from ten healthy controls undergoing cat-
aract surgery were processed using an identical method. The 
aqueous humor and serum levels of VEGF and IL-8 from the 
patient were 880.51 pg/mL and 4,531.5 pg/mL, respectively, 
which were significantly higher than those of the healthy 
control group ( 65.1 ± 42.9 pg/mL and 132.4 ± 62.6 pg/mL, JW Lim, et al. Intravitreal Bevacizumab for Posterior Scleritis
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Fig. 1. (A) Fundus photography at initial presentation demonstrates serous detachment and vitreous haziness in the right eye. (B) 
Mid-phase fundus fluorescein angiography demonstrates disc and vascular leakage involving the macula. (C) B-mode ultrasound scan 
demonstrating diffuse thickening of the posterior coatings of the eye (1.9 mm) together with fluid in the Tenon capsule and the nerve 
sheath. (D) Fundus photography one month post-intravitreal bevacizumab injection, demonstrating resolved posterior scleritis. 
respectively; p < 0.001) The plasma levels of VEGF and IL-8 
from the patient were 105.51 pg/mL and 5.91 pg/mL, re-
spectively, which did not significantly differ from those of 
the healthy control group (255.7 ± 198.9 pg/mL and 17.8 ± 
14.6 pg/mL; p = 0.416 and p = 0.328, respectively). 
Data were compared using Student’s t-test with Bonferroni's 
correction using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, 
USA). A p-value of less than 0.05 was considered statistically 
significant.
Discussion
Posterior scleritis is a common form of scleritis that should 
be suspected in patients who present with periocular pain, 
visual loss, or any of the other signs of posterior scleritis. The 
pathophysiology of posterior scleritis is not fully understood; 
however, during scleral inflammation multiple factors, in-
cluding VEGF, may increase vascular permeability by alter-
ing gap formation between endothelial cells [2]. 
Bevacizumab is a full-length humanized recombinant anti-
body against VEGF. There have been numerous reports re-
garding its safety and efficacy in the off-label treatment of 
choroidal neovascularization and other ischemic-proliferative 
retinopathies [3].
 However, no studies using intravitreal bev-
acizumab as an adjuvant in treating posterior scleritis have 
been published to date. VEGF, a powerful angiogenic sub-
stance, significantly increases vascular permeability and is 
associated with inflammation and immune-mediated pathology. 
Therefore, we hypothesized that VEGF is elevated in posteri-
or scleritis. To test this hypothesis, we measured the aqueous 
humor and plasma levels of VEGF in an affected patient. 
IL-8, a chemokine, not only promotes angiogenesis but also 
displays proinflammatory activity. High levels of IL-8 have 
been detected in patients with uveitis [4,5].  
The current case describes the benefits of using intravitreal 
anti-VEGF therapy in combination with systemic treatment. 
We observed an increased level of VEGF in the aqueous hu-
mor of an affected patient without a corresponding increase 
is serum level. We suggest that the increased VEGF was lo-
cally expressed and was not associated with increased sys-
temic production. The increased levels of VEGF and IL-8 in 
the aqueous humor provide a rationale for the use of intra-
vitreal anti-VEGF therapy.
Although systemic steroid therapy may have a role in dis-
ease treatment, we demonstrated that an intravitreal bev-
acizumab injection could bring on prompt resorption of sub-
retinal fluid, which may be associated with rapidly improved 
vision. The elevated aqueous humor levels of VEGF suggest Korean J Ophthalmol Vol.25, No.4, 2011
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that it plays an important role in intra-ocular inflammation 
and increased vascular permeability in posterior scleritis. 
Local anti-VEGF treatment may be an effective treatment 
option for posterior scleritis. 
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